article thumbnail

AZD1222 US Phase III primary analysis confirms safety and efficacy

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. BARDA, ASPR, HHS.

article thumbnail

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

The Pharma Data

Ann Falsey, Professor of Medicine, University of Rochester School of Medicine, US, and co-lead Principal Investigator for the trial, said: “These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it’s exciting to see similar efficacy results in people over 65 for the first time. JPEO-CBRND.

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How IpsiHand Can Help Stroke Patients Regain Movement through Neurological Rehabilitation

XTalks

The neurological rehabilitation IpsiHand system consists of a biometric headset containing EEG electrodes, a robotic exoskeleton brace worn over the patient’s hand and wrist and a tablet computer. The headset records brain activity on the side of the brain that is not affected by stroke.

Radiology 105
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA). About INOVIO’s DNA Medicines Platform.

DNA 40
article thumbnail

Portable Neuromodulation Stimulator Gets FDA Authorization for MS Treatment

XTalks

Loftus, MD, acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, in a press announcement from the agency. MS affects patients differently with respect to both symptoms and their severity.

article thumbnail

United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis

The Pharma Data

It is characterized by progressive fibrosis, lung scarring, and a radiological pattern known as usual interstitial pneumonia, or UIP. National Library of Medicine at the National Institutes of Health, about 100,000 people are affected in the United States , and 30,000 to 40,000 new cases are diagnosed each year. According to the U.S.

Drugs 40
article thumbnail

Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

The Pharma Data

The WELIREG label contains a boxed warning that exposure to WELIREG during pregnancy can cause embryo-fetal harm. The major efficacy endpoint for the treatment of VHL-associated RCC was ORR measured by radiology assessment using RECIST v1.1 As an inhibitor of HIF-2?, WELIREG reduces transcription and expression of HIF-2?